I agree that this site is using cookies. You can find further informations
here
.
X
Login
My folder (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
Show Desktop-Version
Toggle navigation
Paolo A. Ascierto
1230
results:
Search for persons
X
Format
Online (1230)
Mediatypes
Articles (Online) (458)
Bookchapter (Online) (6)
OpenAccess-fulltext (766)
Sorted by: Relevance
Sorted by: Year
?
1
POLARIS: A phase 2 trial of encorafenib plus binimetinib ev..:
Menzies, Alexander M
;
Long, Georgina V
;
Kohn, Amiee
...
Neuro-Oncology Advances. 6 (2024) 1 - p. , 2024
Link:
https://doi.org/10.1093/..
?
2
Plain language summary of the CheckMate 76K study results: ..:
Kirkwood, John M
;
Vecchio, Michele Del
;
Weber, Jeffrey
...
Future Oncology. 20 (2024) 15 - p. 959-968 , 2024
Link:
https://doi.org/10.2217/..
?
3
Safety and efficacy outcomes of early cessation of anti-PD1..:
Fletcher, Kylie
;
Cortellini, Alessio
;
Ganta, Teja
...
Cancer Letters. 596 (2024) - p. 217001 , 2024
Link:
https://doi.org/10.1016/..
?
4
The side effect registry immuno-oncology (SERIO) – A tool f..:
Ertl, Carolin
;
Ruf, Theresa
;
Mentzer, Dirk
...
European Journal of Cancer. 199 (2024) - p. 113505 , 2024
Link:
https://doi.org/10.1016/..
?
5
Sequential immunotherapy and targeted therapy for metastati..:
Ascierto, Paolo A.
;
Casula, Milena
;
Bulgarelli, Jenny
...
Nature Communications. 15 (2024) 1 - p. , 2024
Link:
https://doi.org/10.1038/..
?
6
Use of artificial intelligence chatbots in clinical managem..:
Burnette, Hannah
;
Pabani, Aliyah
;
von Itzstein, Mitchell S
...
Journal for ImmunoTherapy of Cancer. 12 (2024) 5 - p. e008599 , 2024
Link:
https://doi.org/10.1136/..
?
7
Author Correction: Adjuvant nivolumab in resected stage IIB..:
Kirkwood, John M.
;
Del Vecchio, Michele
;
Weber, Jeffrey
...
Nature Medicine. 30 (2024) 3 - p. 906-906 , 2024
Link:
https://doi.org/10.1038/..
?
8
Pembrolizumab versus placebo as adjuvant therapy in resecte..:
Schadendorf, Dirk
;
Luke, Jason John
;
Ascierto, Paolo A
...
Journal for ImmunoTherapy of Cancer. 12 (2024) 3 - p. e007501 , 2024
Link:
https://doi.org/10.1136/..
?
9
Combined immunotherapy in melanoma patients with brain meta..:
Mandalà, Mario
;
Lorigan, Paul
;
Sergi, Maria Chiara
...
European Journal of Cancer. 199 (2024) - p. 113542 , 2024
Link:
https://doi.org/10.1016/..
?
10
Electronic patient-reported outcomes, fever management, and..:
Mohr, Peter
;
Ascierto, Paolo
;
Addeo, Alfredo
...
EJC Skin Cancer. 2 (2024) - p. 100254 , 2024
Link:
https://doi.org/10.1016/..
?
11
Efficacy and safety of 'Second Adjuvant' therapy with BRAF/..:
Taylor, Amelia M.
;
McKeown, Janet
;
Dimitriou, Florentia
...
European Journal of Cancer. 199 (2024) - p. 113561 , 2024
Link:
https://doi.org/10.1016/..
?
12
COLUMBUS 7-year update: A randomized, open-label, phase III..:
Schadendorf, Dirk
;
Dummer, Reinhard
;
Flaherty, Keith T.
...
European Journal of Cancer. 204 (2024) - p. 114073 , 2024
Link:
https://doi.org/10.1016/..
?
13
Shifting the paradigm: engaging multicellular networks for ..:
Hu, Joyce
;
Ascierto, Paolo
;
Cesano, Alessandra
..
Journal of Translational Medicine. 22 (2024) 1 - p. , 2024
Link:
https://doi.org/10.1186/..
?
14
Randomized, open-label, phase 2 study of nivolumab plus ipi..:
Schenker, Michael
;
Burotto, Mauricio
;
Richardet, Martin
...
Journal for ImmunoTherapy of Cancer. 12 (2024) 8 - p. e008872 , 2024
Link:
https://doi.org/10.1136/..
?
15
Consensus recommendations on management of selumetinib-asso..:
Azizi, Amedeo A
;
Hargrave, Darren
;
Passos, João
...
Neuro-Oncology Practice. , 2024
Link:
https://doi.org/10.1093/..
1-15